/ CompletedNot Applicable [Translation] Bioequivalence studies of flurbiprofen gel patches in healthy trial participants
考察健康试验参与者单次贴敷1贴由安徽京茗药业有限公司提供的氟比洛芬凝胶贴膏(受试制剂 T,规格:每贴(10.0cm×13.6cm)含膏体12g,含氟比洛芬40mg)或 Mikasa Seiyaku Co.,Ltd 持证的氟比洛芬凝胶贴膏(参比制剂 R,规格:每贴含氟比洛芬 40mg(面积 13.6cm×10.0cm,含膏量 12g)) 的药代动力学特征,评价两制剂的生物等效性和安全性,同时考察两制剂的粘附性,皮肤的刺激性,为该受试制剂注册申请提供依据。
[Translation] This study investigated the pharmacokinetic characteristics of a single application of flurbiprofen gel patch (test formulation T, specification: 12g of ointment and 40mg of flurbiprofen per patch (10.0cm×13.6cm)) provided by Anhui Jingming Pharmaceutical Co., Ltd., or flurbiprofen gel patch (reference formulation R, specification: 40mg of flurbiprofen per patch (area 13.6cm×10.0cm, ointment content 12g)) held by Mikasa Seiyaku Co., Ltd. The bioequivalence and safety of the two formulations were evaluated, and their adhesiveness and skin irritation were also investigated to provide a basis for the registration application of the test formulation.
/ CompletedNot Applicable [Translation] Human bioequivalence study of vardenafil hydrochloride orally disintegrating tablets
本试验旨在研究单次空腹口服北京茗泽中和药物研究有限公司研制、华益药业科技(安徽)有限公司生产的盐酸伐地那非口崩片(10 mg)的药代动力学特征;以Alembic Pharmaceuticals Limited持证、生产的盐酸伐地那非口崩片(10 mg)为参比制剂,比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞,评价两制剂的人体生物等效性。
[Translation] This study aimed to investigate the pharmacokinetic characteristics of vardenafil hydrochloride orally disintegrating tablets (10 mg) developed by Beijing Mingze Zhonghe Pharmaceutical Research Co., Ltd. and manufactured by Huayi Pharmaceutical Technology (Anhui) Co., Ltd., after a single oral fasting dose. Using vardenafil hydrochloride orally disintegrating tablets (10 mg) manufactured by Alembic Pharmaceuticals Limited as a reference formulation, the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two formulations were compared to evaluate their bioequivalence in humans.
/ CompletedNot Applicable [Translation] Bioequivalence study of loxoprofen sodium gel patch in healthy volunteers
考察健康受试者单次贴敷1 贴由安徽京茗药业有限公司提供的洛索洛芬钠凝胶贴膏【受试制剂T,规格:每贴(14cm×10cm)含膏量10g,含洛索洛芬钠100mg(以C15H17NaO3 计)】或1 贴由LEAD CHEMICAL CO.,LTD 持证的洛索洛芬钠凝胶膏【参比制剂R,商品名:LOXONIN ® PAP,规格:每贴(14cm×10cm)含膏量10g,含洛索洛芬钠100mg(以C15H17NaO3 计)】的药代动力学特征,评价两制剂的生物等效性和安全性,同时考察两制剂的粘附性及皮肤刺激性,为该受试制剂注册申请提供依据。
[Translation] To investigate the pharmacokinetic characteristics of healthy subjects after a single application of one loxoprofen sodium gel patch provided by Anhui Jingming Pharmaceutical Co., Ltd. [test preparation T, specification: each patch (14cm×10cm) contains 10g of paste, containing 100mg of loxoprofen sodium (calculated as C15H17NaO3)] or one patch of loxoprofen sodium gel patch certified by LEAD CHEMICAL CO., LTD. [reference preparation R, trade name: LOXONIN ® PAP, specification: each patch (14cm×10cm) contains 10g of paste, containing 100mg of loxoprofen sodium (calculated as C15H17NaO3)], and to evaluate the bioequivalence and safety of the two preparations. At the same time, the adhesion and skin irritation of the two preparations were investigated to provide a basis for the registration application of the test preparation.
100 Clinical Results associated with Beijing Mingze Zhonghe Pharmaceutical Research Co., Ltd.
0 Patents (Medical) associated with Beijing Mingze Zhonghe Pharmaceutical Research Co., Ltd.
100 Deals associated with Beijing Mingze Zhonghe Pharmaceutical Research Co., Ltd.
100 Translational Medicine associated with Beijing Mingze Zhonghe Pharmaceutical Research Co., Ltd.